Manipulating TGF-β signaling to optimize immunotherapy for cervical cancer
Cervical cancer is a serious threat to women's health globally. Therefore, identifying key molecules associated with cervical cancer progression is essential for drug development, disease monitoring, and precision therapy. Recently, TGF-β (transforming growth factor-beta) has been identified as...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-10-01
|
| Series: | Biomedicine & Pharmacotherapy |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S0753332223011460 |
| _version_ | 1797686890141319168 |
|---|---|
| author | Shuping Yin Han Cui Shuang Qin Shengnan Yu |
| author_facet | Shuping Yin Han Cui Shuang Qin Shengnan Yu |
| author_sort | Shuping Yin |
| collection | DOAJ |
| description | Cervical cancer is a serious threat to women's health globally. Therefore, identifying key molecules associated with cervical cancer progression is essential for drug development, disease monitoring, and precision therapy. Recently, TGF-β (transforming growth factor-beta) has been identified as a promising target for cervical cancer treatment. For advanced cervical cancer, TGF-β participates in tumor development by improving metastasis, stemness, drug resistance, and immune evasion. Accumulating evidence demonstrates that TGF-β blockade effectively improves the therapeutic effects, especially immunotherapy. Currently, agents targeting TGF-β and immune checkpoints such as PD-L1 have been developed and tested in clinical studies. These bispecific antibodies might have the potential as therapeutic agents for cervical cancer treatment in the future. |
| first_indexed | 2024-03-12T01:11:07Z |
| format | Article |
| id | doaj.art-c8818f5797274e548a50c82c66a5a14b |
| institution | Directory Open Access Journal |
| issn | 0753-3322 |
| language | English |
| last_indexed | 2024-03-12T01:11:07Z |
| publishDate | 2023-10-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Biomedicine & Pharmacotherapy |
| spelling | doaj.art-c8818f5797274e548a50c82c66a5a14b2023-09-14T04:52:46ZengElsevierBiomedicine & Pharmacotherapy0753-33222023-10-01166115355Manipulating TGF-β signaling to optimize immunotherapy for cervical cancerShuping Yin0Han Cui1Shuang Qin2Shengnan Yu3Department of Obstetrics and Gynecology, Changxing People's Hospital of Zhejiang Huzhou, Changxing 313100, ChinaDepartment of Obstetrics and Gynecology, Changxing People's Hospital of Zhejiang Huzhou, Changxing 313100, ChinaDepartment of Radiation Oncology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China; Corresponding authors.Department of Oncology, The First Affiliated Hospital of Chongqing Medical University, 400042 Chongqing, China; Corresponding authors.Cervical cancer is a serious threat to women's health globally. Therefore, identifying key molecules associated with cervical cancer progression is essential for drug development, disease monitoring, and precision therapy. Recently, TGF-β (transforming growth factor-beta) has been identified as a promising target for cervical cancer treatment. For advanced cervical cancer, TGF-β participates in tumor development by improving metastasis, stemness, drug resistance, and immune evasion. Accumulating evidence demonstrates that TGF-β blockade effectively improves the therapeutic effects, especially immunotherapy. Currently, agents targeting TGF-β and immune checkpoints such as PD-L1 have been developed and tested in clinical studies. These bispecific antibodies might have the potential as therapeutic agents for cervical cancer treatment in the future.http://www.sciencedirect.com/science/article/pii/S0753332223011460TGF-βCervical cancerImmunotherapyBispecific antibodyPD-L1 |
| spellingShingle | Shuping Yin Han Cui Shuang Qin Shengnan Yu Manipulating TGF-β signaling to optimize immunotherapy for cervical cancer Biomedicine & Pharmacotherapy TGF-β Cervical cancer Immunotherapy Bispecific antibody PD-L1 |
| title | Manipulating TGF-β signaling to optimize immunotherapy for cervical cancer |
| title_full | Manipulating TGF-β signaling to optimize immunotherapy for cervical cancer |
| title_fullStr | Manipulating TGF-β signaling to optimize immunotherapy for cervical cancer |
| title_full_unstemmed | Manipulating TGF-β signaling to optimize immunotherapy for cervical cancer |
| title_short | Manipulating TGF-β signaling to optimize immunotherapy for cervical cancer |
| title_sort | manipulating tgf β signaling to optimize immunotherapy for cervical cancer |
| topic | TGF-β Cervical cancer Immunotherapy Bispecific antibody PD-L1 |
| url | http://www.sciencedirect.com/science/article/pii/S0753332223011460 |
| work_keys_str_mv | AT shupingyin manipulatingtgfbsignalingtooptimizeimmunotherapyforcervicalcancer AT hancui manipulatingtgfbsignalingtooptimizeimmunotherapyforcervicalcancer AT shuangqin manipulatingtgfbsignalingtooptimizeimmunotherapyforcervicalcancer AT shengnanyu manipulatingtgfbsignalingtooptimizeimmunotherapyforcervicalcancer |